Pure Global
NCT05903027

Gepant treAtments: EffectIveNess and tolERability (GAINER)

Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)
University of Florence·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine
Drug/Device/Intervention
Rimegepant 75 MG Disintegrating Oral Tablet
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
University of Florence
Location
Florence,Padova, Italy
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2023
End date
Jun 01, 2024
Enrollment
100 participants
Primary outcome

Headache pain freedom at 2 hours post-dose during the first attack,Occurrence of treatment-emergent adverse events

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and
 tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic
 migraine patients.

ICD-10 classifications
Migraine without aura [common migraine]Migraine with aura [classical migraine]Other migraineMigraineMigraine, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05903027
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05903027 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Florence and is currently Not yet recruiting. The study focuses on Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.